ORAGENICS FILES ANNUAL REPORT ON FORM 10-K

Core Insights - Oragenics, Inc. has reported significant operational and clinical advancements in 2025, marking a year of strategic transformation and a clear path forward for the company [3][6]. Financial Performance - The company completed a successful capital raise of $16.5 million, strengthening its balance sheet and funding the advancement of its lead candidate, ONP-002, through Phase IIa clinical trials in Australia [4]. - Operating expenses were reduced by 11% year over year, primarily driven by reductions in R&D expenses and overhead salaries [4]. - The net cash used in operations was approximately $9 million, while net cash from financing was approximately $16.8 million [4]. Operational Milestones - Oragenics regained full compliance with NYSE American listing requirements, reflecting improved governance and shareholder alignment [4]. - The company engaged a qualified clinical research organization to lead Phase IIa trial operations across three sites in Australia [4]. - Drug manufacturing was moved from China to the United States, contracting Sterling Pharma Solutions for FDA cGMP manufacturing in Cary, North Carolina [4]. - A strategic partnership was established with Receptor.AI to leverage artificial intelligence in CNS drug discovery, expanding the company's pipeline development capabilities [4]. Clinical Development - The company received Human Research Ethics Committee (HREC) approval in Australia, the final regulatory clearance required to begin patient dosing in the Phase IIa trial of ONP-002 [4]. - The first site initiation visit at the initial Australian clinical trial site was completed, with two additional sites advancing through final Research Governance Office reviews [4]. - All three sites in Australia are expected to complete the RGO review soon, allowing for patient enrollment and dosing to commence [4]. Strategic Focus for 2026 - The CEO emphasized that 2026 will focus on executing the company's strategic plans rather than resetting, with an active exploration of expanding the CNS platform [6]. - The company is pursuing discussions with potential partners regarding the acquisition of additional CNS assets that are synergistic with ONP-002 and its intranasal delivery platform [4].